T-cell therapy of cytomegalovirus and human immunodeficiency virus infection.
about
Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challengeLong-term in vivo provision of antigen-specific T cell immunity by programming hematopoietic stem cells.A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination.Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection.Herpesvirus infections in organ transplant recipientsDNA vaccines to attack cancerCharacterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.PR1 vaccination in myeloid malignancies.Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus.Cross-presentation of HCMV chimeric protein enables generation and measurement of polyclonal T cells.Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma.Generation of cytotoxic T cell responses directed to human leucocyte antigen Class I restricted epitopes from the Aspergillus f16 allergen.T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120.Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.
P2860
Q33551402-DCEB149A-E9F0-4F97-8063-A4957390657CQ33928413-0BD8B46A-79FF-4F50-B7A8-F0F55E0F90C6Q33964131-5B88FAAA-DC0C-45DB-952D-16C1C5491834Q34255648-63AE8A4C-6A94-4971-85E5-04222F286C13Q34255654-FB302588-DE64-46FC-B81E-CB0C210492F6Q34579836-A21B7A51-0CB2-46F5-B0C1-3AE084A4D36DQ35855143-1EB63D8F-2EAD-47C2-B941-E1D4D3B2AE5AQ37132892-57F9DF9F-860A-468F-B302-F4E07CD87EDBQ37259568-B4A0915B-E3A3-4669-9221-0AFCB9063171Q39740808-C3B7C402-F9C9-48AF-B4C2-DD5C0E5568CCQ39895985-095ABA34-15B8-4011-9281-6CC93F1982CFQ40328361-719FA285-EFE7-43EA-9A54-E15D59020F96Q40447738-33E6BE8C-624F-43C3-B08C-8D8BCD0B9461Q40501551-74B11007-5B0C-4BBF-9D87-2CD0665E96CFQ47605886-6DC1D40A-4BEC-4273-AF7F-89F57782653A
P2860
T-cell therapy of cytomegalovirus and human immunodeficiency virus infection.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
T-cell therapy of cytomegalovirus and human immunodeficiency virus infection.
@ast
T-cell therapy of cytomegalovirus and human immunodeficiency virus infection.
@en
type
label
T-cell therapy of cytomegalovirus and human immunodeficiency virus infection.
@ast
T-cell therapy of cytomegalovirus and human immunodeficiency virus infection.
@en
prefLabel
T-cell therapy of cytomegalovirus and human immunodeficiency virus infection.
@ast
T-cell therapy of cytomegalovirus and human immunodeficiency virus infection.
@en
P356
P1476
T-cell therapy of cytomegalovirus and human immunodeficiency virus infection.
@en
P2093
Greenberg PD
Riddell SR
P356
10.1093/JAC/45.SUPPL_4.35
P407
P478
45 Suppl T3
P577
2000-04-01T00:00:00Z